Voyager Therapeutics (VYGR) Receivables - Net (2022 - 2026)

Voyager Therapeutics has disclosed Receivables - Net across 5 years of filings, most recently posting $2.9 million for Q2 2026.

• In Q2 2026, Receivables - Net rose 75.15% year-over-year to $2.9 million; the TTM figure through Jun 2026 stood at $2.9 million (up 75.15% YoY), while the FY2025 annual figure was $1.8 million, up 19.68% from the prior year.
• Receivables - Net came in at $2.9 million for Q2 2026 at Voyager Therapeutics, up from $1.5 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $80.1 million in Q4 2023 to a low of $837000.0 in Q1 2024.
• Average Receivables - Net over 5 years is $11.4 million, with a median of $1.8 million recorded in 2025.
• Year-over-year, Receivables - Net plunged 98.13% in 2024 and jumped 93.91% in 2025.
• Over 5 years, Receivables - Net stood at $10.0 million in 2022, then soared by 701.5% to $80.1 million in 2023, then sank by 98.13% to $1.5 million in 2024, then grew by 17.4% to $1.8 million in 2025, then jumped by 66.5% to $2.9 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $2.9 million in Q2 2026, $1.5 million in Q1 2026, and $1.8 million in Q4 2025.